Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.20372 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von D Aceituno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clifton Insight, Bristol, UK. Hauptthemen laut MEDLINE: Alopecia Areata, Azetidines, Pyrazoles, Sulfonamides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Ritlecitinib and baricitinib are recently approved systemic treatments for severe alopecia areata (AA). Both demonstrated superiority over placebo in hair regrowth measured by the Severity of Alopecia Tool (SALT), but they have not been directly compared in randomized controlled trials (RCTs). We conducted a systematic review of RCTs evaluating treatments in AA and estimated the efficacy and safety of ritlecitinib and baricitinib at Week 24 using Bayesian network meta‐analysis. To adjust and explore effect modifiers, population‐adjusted indirect comparison was performed via multilevel network meta‐regression (ML‐NMR) using ritlecitinib individual patient data (IPD). Co‐primary endpoints were SALT ≤20 and SALT ≤10 at Week 24. Unanchored population adjusted ITCs were also computed to evaluate SALT ≤10 and SALT ≤20 endpoints at Week 48/52. Four RCTs (ALLEGRO 2a [NCT02974868], ALLEGRO 2b/3 [NCT03732807], BRAVE‐AA1 [NCT03570749] and BRAVE‐AA2 [NCT03899259]) were included. No evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on SALT ≤10 (odds ratio, OR: 0.96, 95% credible interval, CrI: 0.18–7.21) and SALT ≤20 (OR: 2.16, 95% CrI: 0.48–16.46) at Week 24 was found. ML‐NMR using ALLEGRO IPD adjusted for sex, SALT score at baseline, duration of current episode and disease duration found evidence of effect modification, although relative efficacy between ritlecitinib 50 mg and baricitinib 4 mg remained unchanged. Unanchored population‐adjusted ITC at Week 48/52 was consistent with previous results. We found similar efficacy between ritlecitinib 50 mg and baricitinib 4 mg. These ITCs was informed by only four RCTs, uncertainty was considerable, and there was evidence of effect modification, highlighting the need for further quality research in AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clifton Insight, Bristol, UK.
- Pontificia Universidad Católica de Chile, Santiago, Chile.
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
- Pfizer Inc, New York, New York, USA.
- HealthEcon Consulting Inc, Ancaster, Ontario, Canada.
- University of Bristol, Bristol, UK.
Förderung
- Pfizer
Zitieren
APA
Aceituno, D., Fawsitt, C. G., Power, G. M., Law, E., Vaghela, S., & Thom, H. (2025). Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20372
Vancouver
Aceituno D, Fawsitt CG, Power GM, Law E, Vaghela S, Thom H. Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20372
BibTeX
@article{Aceituno2025,
author = {Aceituno, D and Fawsitt, C G and Power, G M and Law, E and Vaghela, S and Thom, H},
title = {Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.20372}
}
EUVIMED